Extracted from this filing and checked against the source text.
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
ENDRA Life Sciences Inc. entered into Underwriting Agreement with Newbridge Securities Corporation valued at approximately $4.5 million (effective 2023-04-27).
- Action
- entry
- Agreement
- underwriting
- Counterparty
- Newbridge Securities Corporation
- Value
- approximately $4.5 million
- Effective
- 2023-04-27
Exact text from the filing
On April 27, 2023, ENDRA Life Sciences Inc. (the “Company,” “we,” “us” and “our”) entered into an Underwriting Agreement (the “Underwriting Agreement”) with Newbridge Securities Corporation (the “Underwriter”), relating to the issuance and sale (the “Offering”) of 3,750,000 shares of our common stock and warrants to purchase up to 1,875,000 shares of our common stock.
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
ENDRA Life Sciences Inc. entered into Warrant Agreement with VStock Transfer, LLC (effective 2023-05-02).
- Action
- entry
- Counterparty
- VStock Transfer, LLC
- Effective
- 2023-05-02
Exact text from the filing
On May 2, 2023, the Company entered into a Warrant Agent Agreement setting forth the terms and conditions of the warrants (the “Warrant Agreement”) with its transfer agent, VStock Transfer, LLC, which will act as warrant agent for the warrants.
View on SEC.gov